A protocol for a pilot randomised controlled trial of a Tailored Intervention for people with moderate-to-severe Chronic Obstructive Pulmonary Disease and Co-morbidities delivered by Pharmacists and Consultant respiratory Physicians (TICC-PCP) in Scotland.

IF 1.6 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Richard Lowrie, David Anderson, Aziz Sheikh, Jane Moir, Andrew McPherson, Bethany Stanley, Gillian Cameron, Lynda Attwood, Donald Noble, Elaine Rankine, Jennifer Anderson, Nicola Greenlaw, Fiona Hughes, Emma McIntosh, Samuel Owusu Achiaw, Caitlin Jones, Frances S Mair
{"title":"A protocol for a pilot randomised controlled trial of a Tailored Intervention for people with moderate-to-severe Chronic Obstructive Pulmonary Disease and Co-morbidities delivered by Pharmacists and Consultant respiratory Physicians (TICC-PCP) in Scotland.","authors":"Richard Lowrie, David Anderson, Aziz Sheikh, Jane Moir, Andrew McPherson, Bethany Stanley, Gillian Cameron, Lynda Attwood, Donald Noble, Elaine Rankine, Jennifer Anderson, Nicola Greenlaw, Fiona Hughes, Emma McIntosh, Samuel Owusu Achiaw, Caitlin Jones, Frances S Mair","doi":"10.1186/s40814-025-01681-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Symptomatic chronic obstructive pulmonary disease (COPD) is a global health problem associated with a number of co-morbidities, disproportionately affecting people who are poor. Sub-optimal management of symptomatic COPD and co-morbidities negatively impacts quality of life, ability to work and survival. Previous trials of healthcare professional-led complex interventions have targeted COPD management, but not also simultaneously targeted the treatment of co-morbidities. Recommendations for complex intervention testing include feasibility studies followed by pilot randomised controlled trials (RCTs), including economic and parallel process evaluations. Following a feasibility study, a Tailored, home-based Intervention for people with COPD and Co-morbidities by generalist prescribing Pharmacists collaborating with Consultant respiratory Physicians (TICC PCP) is undergoing pilot testing. The pilot study aims to recruit at least 70% of invited participants within 4 months; deliver TICC PCP to at least 70% of participants in the intervention arm; retain at least 80% of participants (excluding those who died or developed incapacity before the end of the study) until 21-month data collection; and collect at least 90% of in person data at each study time point. In addition, findings from the economic and process evaluations along with information obtained on the proposed quantitative efficacy outcomes inform on the sample size required for a subsequent definitive RCT will help inform on future research.</p><p><strong>Methods: </strong>We describe methods for a multicentre pilot RCT, with parallel economic and qualitative process evaluations of TICC PCP. Set in Glasgow and Edinburgh (Scotland), we plan to recruit 100 people with symptomatic COPD and conduct home-based assessments at baseline and at subsequent three monthly follow up visits over a period of 21 months. Independent researchers will collect extensive health and social care data at recruitment (baseline) before participants are randomised (stratified by site and number of respiratory hospitalisations in the past 12 months), to TICC PCP in addition to usual care (UC), or UC alone. Collected data will include objective and subjective measures of health, healthcare utilisation (including prescribing), home circumstances, health related quality of life, healthcare resource use and intervention costs. Follow up data will be collected three monthly for 21 months. The intervention, delivered by NHS Pharmacists visiting participants at home monthly for 6 months, then every 2 months for the next 6 months, involves clinical assessment and intervention at home including prescribing for COPD and co-morbidities. Pharmacists will also assess and help participants to address wider health needs, e.g. appointment attendance and home equipment. Pharmacists will collaborate mainly with consultant respiratory physicians, and General Practitioners.</p><p><strong>Discussion: </strong>A holistic, 1 year long, individualised home-based intervention for people with symptomatic COPD and co-morbidities may help address unmet health needs. We will utilise the information obtained from this pilot study, including: the recruitment and retention rates; the sample size required to detect a minimal clinically important difference in the proposed efficacy outcomes of interest; the economic analyses; and process evaluation, to determine whether we should progress to a definitive RCT with parallel process and economic evaluation.</p><p><strong>Trial registration: </strong>The trial is registered with the UK Clinical Trials Registry (ISRCTN 43508703).</p>","PeriodicalId":20176,"journal":{"name":"Pilot and Feasibility Studies","volume":"11 1","pages":"105"},"PeriodicalIF":1.6000,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308892/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pilot and Feasibility Studies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40814-025-01681-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Symptomatic chronic obstructive pulmonary disease (COPD) is a global health problem associated with a number of co-morbidities, disproportionately affecting people who are poor. Sub-optimal management of symptomatic COPD and co-morbidities negatively impacts quality of life, ability to work and survival. Previous trials of healthcare professional-led complex interventions have targeted COPD management, but not also simultaneously targeted the treatment of co-morbidities. Recommendations for complex intervention testing include feasibility studies followed by pilot randomised controlled trials (RCTs), including economic and parallel process evaluations. Following a feasibility study, a Tailored, home-based Intervention for people with COPD and Co-morbidities by generalist prescribing Pharmacists collaborating with Consultant respiratory Physicians (TICC PCP) is undergoing pilot testing. The pilot study aims to recruit at least 70% of invited participants within 4 months; deliver TICC PCP to at least 70% of participants in the intervention arm; retain at least 80% of participants (excluding those who died or developed incapacity before the end of the study) until 21-month data collection; and collect at least 90% of in person data at each study time point. In addition, findings from the economic and process evaluations along with information obtained on the proposed quantitative efficacy outcomes inform on the sample size required for a subsequent definitive RCT will help inform on future research.

Methods: We describe methods for a multicentre pilot RCT, with parallel economic and qualitative process evaluations of TICC PCP. Set in Glasgow and Edinburgh (Scotland), we plan to recruit 100 people with symptomatic COPD and conduct home-based assessments at baseline and at subsequent three monthly follow up visits over a period of 21 months. Independent researchers will collect extensive health and social care data at recruitment (baseline) before participants are randomised (stratified by site and number of respiratory hospitalisations in the past 12 months), to TICC PCP in addition to usual care (UC), or UC alone. Collected data will include objective and subjective measures of health, healthcare utilisation (including prescribing), home circumstances, health related quality of life, healthcare resource use and intervention costs. Follow up data will be collected three monthly for 21 months. The intervention, delivered by NHS Pharmacists visiting participants at home monthly for 6 months, then every 2 months for the next 6 months, involves clinical assessment and intervention at home including prescribing for COPD and co-morbidities. Pharmacists will also assess and help participants to address wider health needs, e.g. appointment attendance and home equipment. Pharmacists will collaborate mainly with consultant respiratory physicians, and General Practitioners.

Discussion: A holistic, 1 year long, individualised home-based intervention for people with symptomatic COPD and co-morbidities may help address unmet health needs. We will utilise the information obtained from this pilot study, including: the recruitment and retention rates; the sample size required to detect a minimal clinically important difference in the proposed efficacy outcomes of interest; the economic analyses; and process evaluation, to determine whether we should progress to a definitive RCT with parallel process and economic evaluation.

Trial registration: The trial is registered with the UK Clinical Trials Registry (ISRCTN 43508703).

苏格兰药剂师和呼吸内科顾问医师(TICC-PCP)提供的针对中重度慢性阻塞性肺疾病和合并症患者的量身定制干预的试点随机对照试验方案。
背景:有症状的慢性阻塞性肺疾病(COPD)是一个全球性的健康问题,与许多合并症有关,对穷人的影响尤为严重。对症状性COPD和合并症的次优管理会对生活质量、工作能力和生存产生负面影响。先前的医疗保健专业人员主导的复杂干预试验针对的是慢性阻塞性肺病的管理,但没有同时针对合并症的治疗。对复杂干预试验的建议包括可行性研究,然后是试点随机对照试验(rct),包括经济和平行过程评估。在一项可行性研究之后,由全科处方药剂师与呼吸内科医生(TICC PCP)合作开展的针对慢性阻塞性肺病和合并症患者的量身定制的家庭干预正在进行试点测试。试点研究的目标是在4个月内招募至少70%的受邀参与者;向至少70%的干预组参与者提供TICC PCP;保留至少80%的参与者(不包括那些在研究结束前死亡或丧失工作能力的人),直到21个月的数据收集;并在每个研究时间点收集至少90%的个人数据。此外,经济和过程评估的结果,以及拟议的定量疗效结果所获得的信息,为后续确定的随机对照试验所需的样本量提供了信息,这将有助于为未来的研究提供信息。方法:我们描述了一项多中心试点RCT的方法,并对TICC PCP进行了平行的经济和定性过程评估。在格拉斯哥和爱丁堡(苏格兰),我们计划招募100名有症状的慢性阻塞性肺病患者,并在基线和随后的三个月随访中进行基于家庭的评估,为期21个月。独立研究人员将在招募(基线)时收集广泛的健康和社会护理数据,然后将参与者随机分配(按地点和过去12个月内呼吸道住院次数分层),在常规护理(UC)之外进行TICC PCP治疗,或单独进行UC治疗。收集的数据将包括健康、医疗保健利用(包括处方)、家庭情况、与健康有关的生活质量、医疗保健资源使用和干预费用的客观和主观衡量标准。随访数据每月收集3次,为期21个月。该干预措施由NHS药剂师在6个月内每月上门访问参与者,然后在接下来的6个月内每2个月进行一次,包括临床评估和在家干预,包括为COPD和合并症开处方。药剂师还将评估和帮助参与者解决更广泛的保健需求,例如预约出诊和家庭设备。药剂师将主要与会诊呼吸内科医生和全科医生合作。讨论:对有症状的慢性阻塞性肺病和合并症患者进行为期1年的整体个性化家庭干预可能有助于解决未满足的健康需求。我们会利用从这项先导研究所得的资料,包括:招聘及留任率;在提出的疗效结果中检测最小临床重要差异所需的样本量;经济分析;和工艺评估,以确定我们是否应该进展到具有平行工艺和经济评估的确定性随机对照试验。试验注册:该试验已在英国临床试验注册中心注册(ISRCTN 43508703)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pilot and Feasibility Studies
Pilot and Feasibility Studies Medicine-Medicine (miscellaneous)
CiteScore
2.70
自引率
5.90%
发文量
241
审稿时长
9 weeks
期刊介绍: Pilot and Feasibility Studies encompasses all aspects of the design, conduct and reporting of pilot and feasibility studies in biomedicine. The journal publishes research articles that are intended to directly influence future clinical trials or large scale observational studies, as well as protocols, commentaries and methodology articles. The journal also ensures that the results of all well-conducted, peer-reviewed, pilot and feasibility studies are published, regardless of outcome or significance of findings. Pilot and feasibility studies are increasingly conducted prior to a full randomized controlled trial. However, these studies often lack clear objectives, many remain unpublished, and there is confusion over the meanings of the words “pilot” and “feasibility”. Pilot and Feasibility Studies provides a forum for discussion around this key aspect of the scientific process, and seeks to ensure that these studies are published, so as to complete the publication thread for clinical research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信